Publications by authors named "P Martelletti"
J Headache Pain
December 2024
Article Synopsis
- * In the study, 689 participants were categorized into three groups based on migraine resistance, with significant differences in the number and type of comorbidities found among them.
- * The findings suggest that higher comorbidity rates may contribute to the worsening of migraines, potentially making them harder to treat over time.
J Headache Pain
October 2024
Article Synopsis
- Migraine affects 15.2% of the global population, is a leading cause of disability, especially among women, and remains underdiagnosed and undertreated in many cases.
- The condition displays both common and individual characteristics, with a varied presentation in symptoms, frequency, and response to treatments, influenced by genetic factors.
- Education on migraine management is crucial for improving daily life for patients and reducing the number of individuals needing specialized care, allowing specialists to focus on more complex cases.
Toxins (Basel)
October 2024
Article Synopsis
- * It inhibits the release of pain-related neurotransmitters like glutamate and substance P, and may help treat conditions like nerve entrapment that lead to heightened pain sensitivity.
- * Since 2010, BT-A has been approved for treating chronic migraines and shows promise for other headache types, with studies indicating it can reduce their frequency and severity.
Toxins (Basel)
October 2024
Article Synopsis
- Post-traumatic headache (PTH), common after traumatic brain injury, often mimics migraine and tension-type headaches, but its ideal treatment is still uncertain.
- This review examines the effectiveness of onabotulinumtoxin A (ONA) and anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies in treating PTH, highlighting a lack of substantial evidence for both therapies.
- Results show that while ONA has limited benefits in PTH, it may be more effective than anti-CGRP mAbs, especially since recent trials with fremanezumab did not demonstrate significant results, suggesting targeting CGRP may not work well for PTH.
